Entera Bio Business Summary

Entera Bio Ltd. (ENTX) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing agreements, R&D collaborations, and milestone-based payments, most notably with partners like OPKO Health. The company’s business model is centered on its proprietary N-Tab® technology, a disruptive drug delivery platform designed to transform injectable large-molecule peptides and proteins into oral mini-tablets. Its primary business segments focus on metabolic bone diseases, led by EB613 for post-menopausal osteoporosis and EB612 for hypoparathyroidism, alongside a pipeline of oral GLP-1 and GLP-2 analogs. Within the competitive landscape of pharmaceutical product developers, Entera Bio competes with firms such as Neurogene (NGNE), Enlivex Therapeutics (ENLV), and Shattuck Labs (STTK). Entera distinguishes itself as a specialized leader in oral parathyroid hormone (PTH) delivery, aiming to capture market share from established injectable therapies by improving patient adherence and front-line accessibility. The company was co-founded in 2009 by Dr. Phillip Schwartz, who served as CEO through its 2018 IPO and remains a consultant. The current leadership team is headed by CEO Miranda Toledano, a veteran with over 25 years of experience in biotech investment banking and executive roles at TRIGR Therapeutics and MLV & Co. In February 2026, Entera strengthened its governance by appointing Geno J. Germano as Chairman of the Board; Germano previously served as Group President at Pfizer, where he managed a $14 billion innovative medicines portfolio. Other key executives include Chief of R&D Dr. Gregory Burshtein, an expert in oral peptide formulation, and COO Dr. Hillel Galitzer. The company is backed by notable institutional investors such as Pontifax and strategic partner OPKO Health, whose Executive Vice President, Steven D. Rubin, also serves on Entera’s Board of Directors.